TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.69 CNY | -1.07% |
|
0.00% | -12.97% |
| Mar. 29 | Tianjin Chase Sun Pharmaceutical Co.,Ltd Proposes Final Dividend for 2023 | CI |
| Mar. 01 | Tianjin Chase Sun Pharmaceutical's 2023 Profit Slides 15% on Weak Revenue | MT |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 13,759 | 23,523 | 17,064 | 12,738 | 11,085 | - |
| Enterprise Value (EV) 1 | 13,759 | 23,523 | 17,064 | 12,738 | 11,085 | 11,085 |
| P/E ratio | 24.1 x | 34 x | 27 x | 23.6 x | 15.4 x | 13.2 x |
| Yield | - | - | 0.53% | - | - | - |
| Capitalization / Revenue | - | - | 2.57 x | 2.08 x | 1.49 x | 1.3 x |
| EV / Revenue | - | - | 2.57 x | 2.08 x | 1.49 x | 1.3 x |
| EV / EBITDA | - | - | - | 15.8 x | 9.85 x | 8.42 x |
| EV / FCF | - | - | -690,785,883 x | - | - | - |
| FCF Yield | - | - | -0% | - | - | - |
| Price to Book | - | - | 2.06 x | 1.46 x | 1.19 x | 1.1 x |
| Nbr of stocks (in thousands) | 3,004,155 | 3,004,155 | 3,004,155 | 3,004,155 | 3,004,155 | - |
| Reference price 2 | 4.580 | 7.830 | 5.680 | 4.240 | 3.690 | 3.690 |
| Announcement Date | 2/25/21 | 2/28/22 | 2/27/23 | 2/29/24 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 6,650 | 6,127 | 7,449 | 8,512 |
| EBITDA 1 | - | - | - | 808.5 | 1,125 | 1,316 |
| EBIT 1 | - | - | 712.5 | 511.5 | 813 | 1,000 |
| Operating Margin | - | - | 10.71% | 8.35% | 10.91% | 11.75% |
| Earnings before Tax (EBT) 1 | - | - | 716.4 | 629 | 838 | 1,015 |
| Net income 1 | 575.6 | 688.3 | 624.2 | 529.2 | 706 | 853 |
| Net margin | - | - | 9.39% | 8.64% | 9.48% | 10.02% |
| EPS 2 | 0.1900 | 0.2300 | 0.2100 | 0.1800 | 0.2400 | 0.2800 |
| Free Cash Flow | - | - | -24.7 | - | - | - |
| FCF margin | - | - | -0.37% | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | 0.0300 | - | - | - |
| Announcement Date | 2/25/21 | 2/28/22 | 2/27/23 | 2/29/24 | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | -24.7 | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | 7.78% | 5.97% | 7.6% | 8.5% | - |
| ROA (Net income/ Total Assets) | - | - | - | 4.31% | 5.2% | 5.8% | - |
| Assets 1 | - | - | - | 12,266 | 13,577 | 14,707 | - |
| Book Value Per Share 2 | - | - | 2.760 | 2.900 | 3.110 | 3.360 | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex 1 | - | - | 770 | 345 | 420 | 400 | 390 |
| Capex / Sales | - | - | 11.58% | 5.63% | 5.64% | 4.7% | - |
| Announcement Date | 2/25/21 | 2/28/22 | 2/27/23 | 2/29/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
3.69
CNY
Average target price
4
CNY
Spread / Average Target
+8.40%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -12.97% | 1.53B | |
| -15.13% | 4.51B | |
| -9.75% | 3.15B | |
| +2.14% | 3.1B | |
| -6.82% | 2.42B | |
| +47.87% | 1.97B | |
| +0.09% | 1.65B | |
| -7.89% | 1.68B | |
| +33.40% | 1.38B | |
| +34.29% | 1.3B |
- Stock Market
- Equities
- 300026 Stock
- Financials Tianjin Chase Sun Pharmaceutical Co.,Ltd
